InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
1
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Browse the detailed record of transactions filed by Hoffman Robert E., 董事长兼首席执行官. Director active across 2 companies, notably Kintara Therapeutics, Inc.. In total, 6 reports have been logged. Split: 1 buy · 0 sell. Total volume traded: €23k. History available since 15 February 2022. The latest transaction was disclosed on 28 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Hoffman Robert E.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
85,153 股Common StockSEC:0001628280-26-048014:0
79,873 股0Common StockSEC:0001628280-26-039525:0
5,280 股0Common StockSEC:0001628280-25-028828:0
59,800 股0Common Stock, par value $0.001 per shareSEC:0001493152-23-019950:0
400,145 股0Common StockSEC:0001493152-22-021170:0
55,000 股@ US$0.469100.0% 占其流量Common StockSEC:0000905718-22-000393:0
标准退出：2022年5月16日 (T+90)
6 条申报中的 6 条
About Hoffman Robert E.
Hoffman Robert E. is President-Director General and a declarant. He is linked to Esperion Therapeutics, Inc. as Director and to Kintara Therapeutics, Inc. as President, CEO, and CFO. His 6 filings cover the period from 2022-02-17 to 2026-07-13, and the sampled recent filings show EUR 22815 of buys and EUR 0 of sells, with the modal transaction nature indicated as Attribution.
